Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker shoots for first Chinese acquisition with $764m Trauson offer

This article was originally published in Clinica

Executive Summary

Orthopaedic firm Stryker has become the latest medtech player to look East for growth, making a $764 million offer for Chinese trauma and specialist Trauson. The offer, worth HK$7.50 ($0.97) per Trauson share, gives the firm an enterprise value of around $685 million. It also represents a 45% premium over Trauson's share price of HK$5.16 on 8 January, when trading was halted on the Hong Kong Stock Exchange.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT099869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel